Literature DB >> 18413444

EULAR recommendations for the management of primary small and medium vessel vasculitis.

C Mukhtyar1, L Guillevin, M C Cid, B Dasgupta, K de Groot, W Gross, T Hauser, B Hellmich, D Jayne, C G M Kallenberg, P A Merkel, H Raspe, C Salvarani, D G I Scott, C Stegeman, R Watts, K Westman, J Witter, H Yazici, R Luqmani.   

Abstract

OBJECTIVES: To develop European League Against Rheumatism (EULAR) recommendations for the management of small and medium vessel vasculitis.
METHODS: An expert group (consisting of 10 rheumatologists, 3 nephrologists, 2 immunologists, 2 internists representing 8 European countries and the USA, a clinical epidemiologist and a representative from a drug regulatory agency) identified 10 topics for a systematic literature search using a modified Delphi technique. In accordance with standardised EULAR operating procedures, recommendations were derived for the management of small and medium vessel vasculitis. In the absence of evidence, recommendations were formulated on the basis of a consensus opinion.
RESULTS: In all, 15 recommendations were made for the management of small and medium vessel vasculitis. The strength of recommendations was restricted by low quality of evidence and by EULAR standardised operating procedures.
CONCLUSIONS: On the basis of evidence and expert consensus, recommendations have been made for the evaluation, investigation, treatment and monitoring of patients with small and medium vessel vasculitis for use in everyday clinical practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413444     DOI: 10.1136/ard.2008.088096

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  246 in total

Review 1.  Treatment of ANCA-associated vasculitis, where to go?

Authors:  Cees G M Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 2.  Complications of long-term therapy for ANCA-associated systemic vasculitis.

Authors:  Nadezhda Wall; Lorraine Harper
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

Review 3.  ANCA-associated vasculitides--advances in pathogenesis and treatment.

Authors:  Min Chen; Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

4.  [Polyarteritis nodosa: differential diagnostics and therapy].

Authors:  J H Schirmer; K Holl-Ulrich; F Moosig
Journal:  Z Rheumatol       Date:  2014-12       Impact factor: 1.372

5.  [Therapy of vasculitides: according to recommendations of the European League Against Rheumatism (EULAR) and European Vasculitis Study Group (EUVAS)].

Authors:  J U Holle; F Moosig; W L Gross
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

6.  Spontaneous fusion between cancer cells and endothelial cells.

Authors:  K Mortensen; J Lichtenberg; P D Thomsen; L-I Larsson
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

Review 7.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

Review 8.  ANCA-associated vasculitides-lessons from the adult literature.

Authors:  Joannis Vamvakopoulos; Caroline O Savage; Lorraine Harper
Journal:  Pediatr Nephrol       Date:  2010-04-01       Impact factor: 3.714

9.  Delays in recognition and management of giant cell arteritis: results from a retrospective audit.

Authors:  Amara N Ezeonyeji; Frances A Borg; Bhaskar Dasgupta
Journal:  Clin Rheumatol       Date:  2010-11-18       Impact factor: 2.980

10.  Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritis.

Authors:  Teresa K Chen; Christine Murakami; Rebecca L Manno; Duvuru Geetha
Journal:  Semin Arthritis Rheum       Date:  2014-03-28       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.